Creative Medical Technology (NASDAQ:CELZ) Stock Price Down 4.2% – What’s Next?

Shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) traded down 4.2% during trading on Monday . The stock traded as low as $1.82 and last traded at $1.82. 12,983 shares traded hands during trading, a decline of 52% from the average session volume of 26,949 shares. The stock had previously closed at $1.90.

Wall Street Analysts Forecast Growth

CELZ has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

Creative Medical Technology Stock Performance

The firm has a market cap of $4.70 million, a price-to-earnings ratio of -0.63 and a beta of 2.08. The business’s 50-day moving average is $2.02 and its 200-day moving average is $2.78.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is owned by institutional investors and hedge funds.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.